Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Waymo Issues Recall After Reports of Self-Driving Cars Illegally Passing School Buses in Texas 
Lockheed Martin Secures $1.14 Billion Contract Boost for F-35 Production 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Visa to Move European Headquarters to London’s Canary Wharf 
Walgreens Boots Alliance Inc. (NASDAQ: WBA) is reportedly close to a $10 billion buyout deal with private equity firm Sycamore Partners, according to The Wall Street Journal. The deal, which could be finalized by Thursday, would take the struggling pharmacy chain private.
Sycamore is expected to offer between $11.30 and $11.40 per share in cash, with potential performance-based incentives. If the acquisition proceeds, Sycamore is likely to retain Walgreens' core U.S. retail operations while divesting or taking public other parts of the company.
Once a dominant force in U.S. pharmacy retail, Walgreens has seen its market value plummet from over $100 billion in 2015 to below $8 billion by late 2024. The company has struggled with declining prescription margins and an unsuccessful push into primary care. Under CEO Tim Wentworth, Walgreens has been closing underperforming stores in an effort to stabilize operations.
Sycamore, known for retail investments like its 2017 acquisition of Staples, aims to reposition Walgreens for long-term growth.
